Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

This study has been completed.
Wake Forest University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 21, 2007
Last updated: May 20, 2016
Last verified: May 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2016
  Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)